Coya Therapeutics, Inc. (COYA)
(Delayed Data from NSDQ)
$5.50 USD
-0.24 (-4.18%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $5.61 +0.11 (2.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
COYA 5.50 -0.24(-4.18%)
Will COYA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for COYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COYA
Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates
COYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?
Other News for COYA
COYA forms 180 Bearish Setup on September 20
Is COYA ready to move higher? Stochastic Buy Signal shows up after rocketing 6.1%
Lower Bollinger Band Walk appears for COYA after 4.59% move
Coya Therapeutics, Inc. (COYA) Gets a Buy from Lake Street
COYA: Analyst Jason Kolbert Maintains 'Buy' Rating with $18 Target | COYA Stock News